QIAGEN's new HPV test can effectively reduce cervical cancer risk
-
Last Update: 2020-07-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
research shows that a specialized human papillomavirus (HPV) test developed by QIAGEN with the support of the Global Non-Profit Health Organization (PATH) has the potential to reduce the incidence of cervical cancer in low-income regions of the worldThe study was presented at the 24th International Papillomavirus Symposium in BeijingThe test, called FastHPV, is a molecular test used to detect the type of carcinogenic HPV (human papillomavirus)According to the report,womenonly three tests and appropriate treatment in their lifetime can reduce the incidence of cervical cancer by as much as 56 percent(New Asia)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
